These drugs are known as glucagon-like peptide-1 (GLP-1) receptor agonists, and they work by mimicking the naturally occurring GLP-1 hormone in the gut
The API is the peptide itself, but the drug product is the final form that the patient uses, which for most GLP-1s, is a sophisticated autoinjector pen
Look for formulations that specifically mention complexion enhancer properties
were often deficient in nutrients
During 1,414,144 person-years of follow-up, cholangiocarcinoma occurred among 222 patients with use of DPP4 inhibitors (incidence rate, 26 per 100,000 patient-years) and among 128 patients with use of sulfonylureas (incidence rate, 23 per 100,000 patient-years)
Additionally, these gastrointestinal conditions could be fatal if patients do not receive proper medical attention